ClinicalTrials.gg

Program

leniolisib

Also written as “Leniolisib” and “CDZ173”.

Its studies are mostly in Common Variable Immunodeficiency · Primary Immunodeficiency Diseases · Lymphadenopathy, led by 2 companies.

Furthest: phase 3, since Aug 4, 20169 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Group74 open or runningphase 3since Aug 4, 2016Aug 4, 2016Nov 30, 2026phase 3 · NCT05438407
Novartis20 open or runningphase 3since Feb 24, 2015Feb 24, 2015none ahead

Also a collaborator on its studies: aixial-group, cmic-co-ltd-japan, fortrea, laboratory-corporation-of-america and axial-biotech-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2015First study: phase 3 study in Common Variable ImmunodeficiencyNew to NovartisNovartis · NCT02435173 · 37 enrolled · United States, Belarus, Czechia and more
  2. May 16, 2016Phase 2 study in Primary Sjögren's SyndromeNovartis · NCT02775916 · 30 enrolled · Germany, Hungary
  3. Aug 4, 2016Pharming Group's first study: phase 3 study in Activated PI3K-delta SyndromeNew to Pharming GroupPharming Group · NCT02859727 · 37 enrolled · United States, Belarus, Czechia and more
  4. May 20, 2022Phase 3 study in APDSPharming Group · NCT05438407 · 15 enrolled · United States, France, Japan
  5. Oct 17, 2022Phase 3 study in APDSPharming Group · NCT05693129 · 16 enrolled · United States, Japan, Portugal and more
  6. Nov 21, 2023Phase 3 study in APDS Gene MutationPharming Group · NCT06249997 · 3 planned · Japan
  7. Jul 17, 2024Phase 2 study in Primary Immunodeficiency DiseasesPharming Group · NCT06549114 · 13 enrolled · United States
  8. Mar 12, 2025Phase 2 study in Common Variable ImmunodeficiencyPharming Group · NCT06897358 · 27 enrolled · United States, Spain, United Kingdom
  9. May 8, 2025Phase 2 study in PIDs Linked to PI3KPharming Group · NCT06990529 · 12 enrolled · United States, Spain, United Kingdom

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in APDSPharming Group · NCT05438407
  2. Jul 9, 2028Primary completion: phase 3 study in APDSPharming Group · NCT05693129
  3. Aug 12, 2029Primary completion: phase 2 study in PIDs Linked to PI3KPharming Group · NCT06990529

TargetBeta

PIK3CD →read by rule
“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
idelalisibruleGilead Sciencesphase 428
duvelisibruleSecuraBiophase 326
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24
roginolisibruleioncturaphase 24

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06990529PIDs Linked to PI3K · United States, Spain, United Kingdom2Active, not recruitingPharming GroupAug 12, 202912
NCT06897358Common Variable Immunodeficiency · United States, Spain, United Kingdom2CompletedPharming GroupAug 12, 202627
NCT06549114Primary Immunodeficiency Diseases · United States2CompletedPharming GroupJun 23, 202613
NCT06249997APDS Gene Mutation · Japan3RecruitingPharming GroupJan 31, 20253
NCT05693129APDS · United States, Japan, Portugal and more3Active, not recruitingPharming GroupJul 9, 202816
NCT05438407APDS · United States, France, Japan3Active, not recruitingPharming GroupNov 30, 202615
NCT02859727Activated PI3K-delta Syndrome · United States, Belarus, Czechia and more3TerminatedPharming GroupJan 30, 202537
NCT02775916Primary Sjögren's Syndrome · Germany, Hungary2CompletedNovartisMay 17, 201730
NCT02435173Common Variable Immunodeficiency · United States, Belarus, Czechia and more3CompletedNovartisAug 16, 202137

How it is read

Names in the registry

  • “Leniolisib”, 6 entries
  • “CDZ173”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.